Study guide

Arthritis, autoimmune disease and geriatric care

AMC CAT MCQ Examination AMC Part 1

Track your progress as you read

Finished sections get a check mark.

1 Acute Coronary Syndromes & ECG Localization

ACS recognition and ECG localisation Reperfusion and infarction complications

2 Heart Failure, Cardiogenic Shock & Cardiac Arrhythmias

Heart failure assessment and treatment Arrhythmias and conduction emergencies

3 Systemic Hypertension & Peripheral Vascular Disease

Blood pressure and cardiovascular risk Secondary hypertension and arterial disease

4 Valvular Heart Disease, Infective Endocarditis & Pericarditis

Aortic and mitral valve disease Endocarditis and pericardial emergencies

5 Asthma & COPD Acute Flares and Maintenance

Asthma and COPD diagnosis and maintenance Acute asthma and COPD exacerbations

6 Pneumonia, pleural disease and respiratory failure

Pneumonia and infected pleural collections Pulmonary embolism, effusions and pneumothorax Respiratory failure, ARDS and sepsis

7 GI bleeding, bowel inflammation and malabsorption

GI bleeding assessment and resuscitation Varices, ulcers, reflux and lower GI bleeding IBD patterns and severe colitis assessment IBD treatment, coeliac disease and IBS

8 Chronic Liver Disease, Cirrhosis Complications & Acute Hepatitis

Cirrhosis diagnosis and prognosis Decompensation, viral hepatitis and surveillance

9 Diabetes, thyroid and adrenal disease

Diabetes diagnosis and ongoing care DKA, HHS and complication monitoring Thyroid disease assessment Thyroid emergencies and adrenal disease

10 Acute Kidney Injury, Chronic Kidney Disease & Fluid/Electrolyte Emergencies

AKI and chronic kidney disease Potassium and sodium emergencies

11 Anaemias, Inflammatory Arthropathies & Geriatric Comprehensive Assessment

Anaemia, bruising and blood disorders Arthritis, autoimmune disease and geriatric care

12 Evaluation of the Acute Abdomen, Peritonitis & Appendicitis

Abdominal pain, peritonitis and resuscitation Appendicitis diagnosis and treatment Perforation and mesenteric ischaemia

13 Small and Large Bowel Obstruction & Colorectal Surgical Pathology

Small bowel obstruction Colonic obstruction, volvulus and cancer recognition Colorectal care, diverticulitis and anorectal symptoms

14 Gallbladder Disease, Biliary Tract Infections & Acute Pancreatitis

Gallstones and biliary obstruction Cholangitis and pancreatitis diagnosis Pancreatitis severity and treatment

15 Advanced Trauma Life Support, Primary Survey & Life-Threatening Thoracic Injuries

Trauma primary survey and adjuncts Chest trauma and immediate threats

16 Traumatic Brain Injury, Intracranial Haemorrhage & Spinal Cord Clearance

Head injury, imaging and haemorrhage Herniation and spinal cord injury

17 Major Fractures, Joint Dislocations & Acute Compartment Syndrome

Fracture assessment and open injuries Compartment syndrome, dislocations and pelvic injury

18 Thermal Burns, Haemorrhagic Shock Resuscitation & Surgical Wound Care

Burn assessment and fluid resuscitation Bleeding shock, wound care and tetanus

19 Aortic Aneurysms & Acute Arterial Limb Ischaemia

Aneurysm recognition and planned care Ruptured aneurysm and acute limb ischaemia

20 Urological Emergencies, Testicular Torsion & Haematuria Investigation

Retention, stones and obstructed infection Scrotal pain and haematuria

21 Preoperative Risk Stratification & Postoperative Surgical Complications

Preoperative assessment and medicines Postoperative complications and prevention

22 Early Pregnancy Bleeding, Ectopic Pregnancy & Antenatal Screening

Miscarriage and ectopic pregnancy Antenatal screening and early-pregnancy comparisons

23 Hypertensive Disorders of Pregnancy & Medical Complications in Pregnancy

Pregnancy hypertension and preeclampsia Eclampsia, HELLP and antepartum bleeding

24 Intrapartum Monitoring, Postpartum Haemorrhage & Obstetric Emergencies

Labour physiology and CTG assessment CTG response and postpartum haemorrhage Obstetric emergencies and preterm birth

25 Abnormal Uterine Bleeding, Pelvic Pain & Endometriosis

Abnormal bleeding and structural causes Endometrial sampling and endometriosis PCOS diagnosis and long-term care

26 Contraception, Emergency Contraception & Pregnancy Termination

Contraceptive choice and missed pills Emergency contraception and abortion

27 Australian Cervical Screening Program & Gynaecological Malignancies

Cervical screening and cervical cancer Endometrial and ovarian cancer

28 Neonatal Resuscitation, Congenital Conditions & Neonatal Jaundice

Newborn resuscitation, Apgar and cyanosis Neonatal jaundice assessment Jaundice treatment and congenital screening

29 Developmental Milestones, Growth Charts & Failure to Thrive

Developmental milestones Regression, autism and support Faltering growth and developmental comparisons

30 The Limping Child, Septic Arthritis vs Transient Synovitis & Paediatric Hip Conditions

Limp assessment and septic-joint risk Joint-infection management and Perthes disease SUFE and paediatric hip comparisons

31 Croup, Bronchiolitis, Paediatric Asthma & Anaphylaxis

Croup Bronchiolitis Paediatric asthma Paediatric anaphylaxis

32 Evaluation of the Febrile Child, Sepsis & Meningococcal Disease

Febrile neonates and young infants Meningococcal disease and paediatric sepsis Bacterial meningitis and CSF interpretation Kawasaki disease and follow-up

33 Paediatric Surgical Abdomen, Dehydration & Child Protection / Non-Accidental Injury

Pyloric stenosis Intussusception and dehydration Child protection and injury assessment

34 The Mental State Examination & Suicide Risk Stratification

Mental state examination and psychotic symptoms Suicide formulation and mental health law

35 Major Depressive Disorder, Bipolar Affective Disorder & Mood Stabilisers

Depression assessment and treatment Serotonin toxicity and bipolar presentations Mood stabilisers and ECT

36 Generalised Anxiety, Panic Disorder, PTSD & Obsessive-Compulsive Disorder

Anxiety, panic and agoraphobia OCD and trauma-related disorders

37 Schizophrenia, Acute Psychosis & Antipsychotic Management

Psychosis assessment and antipsychotics Clozapine and severe adverse effects

38 Substance Use Disorders & Acute Withdrawal Syndromes

Substance disorders and alcohol withdrawal Wernicke disease, opioids and stimulants

39 Delirium vs Dementia, Perinatal Mood Disorders & Paediatric Psychiatry

Delirium and dementia assessment Cognitive behaviour, perinatal and childhood psychiatry

40 Medicare, PBS, AHPRA & Good Medical Practice Framework

Australian health services and Medicare PBS access and professional registration Professional boundaries and notifications

41 Informed Consent (Rogers v Whitaker), Mental Capacity & Involuntary Treatment

Consent, material risks and young people Capacity, refusal and substitute decisions

42 Patient Privacy, Confidentiality Exceptions & Mandatory Notifications

Privacy, disclosure and child reporting Driving fitness and threat disclosure

43 First Nations health and preventive care

First Nations health, determinants and cultural safety Community care, Item 715 and CTG medicines Immunisation and cancer screening entry points Screening pathways and primary CVD prevention

44 Epidemiological Metrics, Clinical Study Designs & Notifiable Communicable Diseases

Epidemiology, calculations, bias and surveillance

45 Neurological presentations

Stroke, TIA and focal weakness Headache, facial pain and vertigo Seizures, collapse and altered consciousness Numbness, movement disorders and generalised weakness

46 Musculoskeletal pain

Back, neck, bone and soft tissue pain

47 Eye presentations

Altered vision and retinal disease Red eye, ocular injury and discharge

48 Ear, nose, throat and oral health

Ear pain, hearing loss and tinnitus Nasal problems, neck lumps, hoarseness and dysphagia Toothache, mouth symptoms, dry mouth and halitosis

49 Skin, hair and nails

Rash, itch, infection and skin ulcers Skin lesions, hair loss and nail abnormalities

50 Breast health and feeding

Breast lumps, discharge and breastfeeding problems

51 Sexual and reproductive presentations

Genital symptoms, discharge and pelvic infection Menopause, prolapse and urinary symptoms Infertility and sexual dysfunction

52 Palliative care and carers

The dying patient, symptoms and carers

53 Eating disorders and personality care

Eating disorders, obesity and weight change Personality difficulties, self-harm and complex care

54 Sleep presentations

Insomnia, snoring and daytime sleepiness

55 Poisoning, resuscitation and environmental emergencies

Poisoning, toxidromes and antidote decisions Cardiopulmonary arrest, choking and emergency help Bites, stings, heat, cold and drowning

56 Communication, rights and professional practice

Communication, handover, errors and complaints Healthcare rights, inclusive care and equitable access Certificates, deaths, CPD and supervision Telehealth, images, prescribing and doctors' health

57 Genetics, research and donation

Genetic testing, research and organ donation

58 Travel, fever and outbreaks

Fever, travellers and outbreak response

Arthritis, autoimmune disease and geriatric care

Key Takeaways Explain This Topic AI

Crystals in joint fluid do not exclude concurrent septic arthritis.

Suspected giant cell arteritis requires prompt treatment to protect vision.

A 4AT score of at least 4 suggests delirium and needs clinical assessment.

Last updated: October 2026

Inflammatory Arthropathies & Crystal Diseases

Accurate differentiation between inflammatory synovitis, crystal-induced arthritis, and septic arthritis is essential to prevent permanent joint destruction.

Joint Fluid Aspiration Characteristics

Normal : Macroscopic Appearance: Clear, straw, viscous; Leucocyte Count ( cells/ μ L \text{cells/}\mu\text{L} cells/ μ L ): < 200 < 200 < 200 ; Neutrophils: < 25 % < 25\% < 25% ; Polarized Light Microscopy: No crystals

Osteoarthritis (Non-inflammatory) : Macroscopic Appearance: Clear, yellow, viscous; Leucocyte Count ( cells/ μ L \text{cells/}\mu\text{L} cells/ μ L ): 200 − 2 , 000 200 - 2,000 200 − 2 , 000 ; Neutrophils: < 25 % < 25\% < 25% ; Polarized Light Microscopy: No crystals

Rheumatoid / Inflammatory Arthritis : Macroscopic Appearance: Translucent/turbid, yellow; Leucocyte Count ( cells/ μ L \text{cells/}\mu\text{L} cells/ μ L ): 2 , 000 − 50 , 000 2,000 - 50,000 2 , 000 − 50 , 000 ; Neutrophils: 50 − 75 % 50 - 75\% 50 − 75% ; Polarized Light Microscopy: No crystals

Gout : Macroscopic Appearance: Turbid, milky; Leucocyte Count ( cells/ μ L \text{cells/}\mu\text{L} cells/ μ L ): 10 , 000 − 50 , 000 + 10,000 - 50,000+ 10 , 000 − 50 , 000 + ; Neutrophils: > 75 % > 75\% > 75% ; Polarized Light Microscopy: Needle-shaped, strongly negatively birefringent crystals (bright yellow parallel to axis)

Pseudogout (CPPD) : Macroscopic Appearance: Turbid, cloudy; Leucocyte Count ( cells/ μ L \text{cells/}\mu\text{L} cells/ μ L ): 10 , 000 − 50 , 000 + 10,000 - 50,000+ 10 , 000 − 50 , 000 + ; Neutrophils: > 75 % > 75\% > 75% ; Polarized Light Microscopy: Rhomboid-shaped, weakly positively birefringent crystals (bright blue parallel to axis)

Septic Arthritis : Macroscopic Appearance: Opaque, purulent, thick; Leucocyte Count ( cells/ μ L \text{cells/}\mu\text{L} cells/ μ L ): > 50 , 000 > 50,000 > 50 , 000 (often > 100 , 000 > 100,000 > 100 , 000 ); Neutrophils: > 90 % > 90\% > 90% ; Polarized Light Microscopy: Gram stain/culture may identify infection; negative results do not exclude it, and crystals may coexist

Clinical Profiles of Arthropathies

Rheumatoid Arthritis (RA):

Chronic, systemic autoimmune polyarthritis with predilection for small joints of the hands and feet: metacarpophalangeal (MCP), proximal interphalangeal (PIP), and metatarsophalangeal (MTP) joints, alongside wrists. Distal interphalangeal (DIP) joints and the thoracolumbar spine are characteristically spared .

Symptoms: Symmetrical joint pain, swelling, and early morning stiffness > 60 minutes > 60\text{ minutes} > 60 minutes that improves with physical activity.

Serology: Anti-cyclic citrullinated peptide (anti-CCP) antibodies are highly specific ( > 95 − 98 % > 95-98\% > 95 − 98% ) and predict aggressive erosive disease. Rheumatoid Factor (RF) is sensitive ( 70 − 80 % 70-80\% 70 − 80% ) but less specific.

Pharmacotherapy: Early introduction of disease-modifying antirheumatic drugs (DMARDs) is mandatory to prevent irreversible erosive joint destruction:

First-Line csDMARD: Methotrexate ( 10 − 25 mg 10 - 25\text{ mg} 10 − 25 mg once weekly) co-prescribed with folic acid ( 5 mg 5\text{ mg} 5 mg once weekly on a different day to reduce GI toxicity, stomatitis, and hepatic transaminitis). Baseline tests: full blood count, liver function tests, renal function, and chest X-ray. Regular FBC and LFT monitoring every 4-8 weeks is mandatory.

Biologic DMARDs: TNF-alpha inhibitors (adalimumab, infliximab, etanercept). Pre-treatment screening for latent tuberculosis (QuantiFERON-TB Gold or Mantoux test) , Hepatitis B, and Hepatitis C is mandatory prior to commencement to prevent fatal reactivation.

Gout:

Deposition of monosodium urate (MSU) crystals in joints following chronic hyperuricaemia. Characterized by sudden, excruciating monoarthritis, classically affecting the first metatarsophalangeal joint ( podagra ) in > 50 % > 50\% > 50% .

Acute Treatment: High-dose NSAIDs (naproxen, indomethacin), low-dose oral colchicine ( 1 mg 1\text{ mg} 1 mg stat, followed by 0.5 mg 0.5\text{ mg} 0.5 mg 1 hour later, then 0.5 mg 0.5\text{ mg} 0.5 mg bd; avoid old toxic regimens), or intra-articular/systemic corticosteroids.

Long-Term Urate-Lowering Therapy (ULT): Indicated for recurrent attacks ( ≥ 2 / year \ge 2/\text{year} ≥ 2/ year ), presence of tophi, radiological erosions, or renal calculi. First-line is allopurinol (xanthine oxidase inhibitor), started at 100 mg 100\text{ mg} 100 mg daily and titrated to target serum urate < 0.36 mmol/L < 0.36\text{ mmol/L} < 0.36 mmol/L ( < 0.30 mmol/L < 0.30\text{ mmol/L} < 0.30 mmol/L if tophi present). Mandatory rule: Co-prescribe prophylactic colchicine ( 0.5 mg 0.5\text{ mg} 0.5 mg daily) or an NSAID for the first 3 to 6 months of allopurinol initiation to prevent acute mobilization flares.

Pseudogout (Calcium Pyrophosphate Dihydrate [CPPD]):

Rhomboid, positively birefringent crystals in synovial fluid; predilection for large joints (knees, wrists). Plain radiographs demonstrate chondrocalcinosis (calcification of the articular cartilage or menisci). Associated with haemochromatosis, primary hyperparathyroidism, and hypomagnesaemia.

Septic Arthritis:

Medical and surgical emergency. Presents with an acutely warm, erythematous, swollen, exquisitely tender joint with severe restriction of both active and passive range of motion, accompanied by fever and systemic toxicity. Most commonly Staphylococcus aureus (including MRSA) or Neisseria gonorrhoeae in young adults.

Suspected septic arthritis: Aspirate and culture urgently, but do not delay antibiotics/resuscitation in sepsis or shock. A negative Gram stain, cell count below 50,000 or crystals cannot safely exclude infection. Obtain orthopaedic input and select antibiotics for the patient and local microbiology.

  • Systemic Autoimmune Conditions: SLE & Giant Cell Arteritis
  • Systemic Lupus Erythematosus (SLE)

Multisystem autoimmune disease driven by immune complex deposition affecting women of childbearing age ( 9 : 1 9:1 9 : 1 female-to-male ratio).

Manifestations: Malar 'butterfly' rash (sparing nasolabial folds), discoid lupus, photosensitivity, non-scarring alopecia, painless oral ulcers, non-erosive polyarthritis, serositis (pleurisy, pericarditis), lupus nephritis, and haematological cytopenias.

Serological Markers:

Anti-Nuclear Antibody (ANA): Sensitive ( > 95 % > 95\% > 95% ); ideal initial screening test; negative ANA virtually excludes active SLE.

Anti-double-stranded DNA (anti-dsDNA): Highly specific ( > 95 % > 95\% > 95% ); titres correlate with disease flares and active lupus nephritis .

Anti-Smith (anti-Sm): Highly specific for SLE.

Anti-Ro (SSA) and Anti-La (SSB): Associated with photosensitivity, secondary Sjögren syndrome, and neonatal lupus (causing congenital complete heart block in the infant).

Serum Complement (C3, C4): Depressed during active immune-complex consumption flares.

SLE treatment: Hydroxychloroquine is recommended for most patients unless contraindicated, with dose/risk-aware retinal surveillance. Higher-risk patients need earlier monitoring. Nephritis and other organ disease require rheumatology/nephrology assessment and phenotype-specific immunosuppression.

Giant Cell Arteritis (GCA / Temporal Arteritis)

Granulomatous large-vessel vasculitis affecting individuals > 50 years > 50\text{ years} > 50 years of age , strongly associated with Polymyalgia Rheumatica (PMR) (bilateral aching and morning stiffness in the shoulder and pelvic girdles).

Clinical Presentation:

  • New-onset localized headache (predominantly temporal)
  • Scalp tenderness (pain when combing hair or resting head on a pillow)

Jaw claudication (fatigue and cramping pain in masseter muscles while chewing food, highest specificity for GCA)

Visual symptoms: Amaurosis fugax, diplopia, or sudden painless unilateral visual loss caused by anterior ischaemic optic neuropathy (AION) due to posterior ciliary artery occlusion.

GCA investigations: ESR and CRP are often raised, but normal results do not exclude disease. Urgent ultrasound in an experienced service and/or biopsy support diagnosis; visual threat warrants immediate glucocorticoids and specialist care without awaiting tests.

Definitive Diagnosis: Temporal artery biopsy demonstrating transmural granulomatous inflammation with multinucleated giant cells and disruption of the internal elastic lamina. Because inflammation is segmental ('skip lesions'), a biopsy length of ≥ 1.5 − 2.0 cm \ge 1.5 - 2.0\text{ cm} ≥ 1.5 − 2.0 cm is required. Temporal artery duplex ultrasound showing a non-compressible hypoechoic wall oedema ('halo sign') is an excellent non-invasive adjunct.

Critical Emergency Rule: If Giant Cell Arteritis is suspected, commence immediate high-dose systemic corticosteroids (oral prednisolone 1 mg/kg/day, typically 50-60 mg daily, or intravenous methylprednisolone 500-1000 mg daily for 3 days if visual symptoms are present) prior to performing a temporal artery biopsy. Biopsy remains diagnostic for up to 1-2 weeks following steroid initiation, and delayed treatment risks permanent, irreversible bilateral blindness.

Comprehensive Geriatric Assessment (CGA)

The Comprehensive Geriatric Assessment is a multidisciplinary diagnostic process evaluating medical, psychological, and functional capabilities of frail older adults to coordinate integrated treatment plans.

1. Delirium: Identification and Management

Delirium is an acute, fluctuating neurocognitive syndrome characterized by disturbances in attention, awareness, and baseline cognition. It is categorized into hyperactive, hypoactive (most common, characterized by lethargy, reduced motor activity, and withdrawal; associated with worse prognosis), and mixed subtypes.

Delirium screening: 4AT at least 4 suggests delirium and requires clinical assessment for acute change and causes. CAM assesses acute/fluctuating course, inattention and either disorganised thinking or altered consciousness. Neither replaces a search for reversible illness.

  • Acute onset and fluctuating course, AND
  • Inattention, AND EITHER
  • Disorganized thinking, OR

Altered level of consciousness.

Precipitating Factors: The 'PINCH ME' Mnemonic:

  • P — Pain (inadequately controlled)
  • I — Infection (urinary tract infection, pneumonia, cellulitis)
  • N — Nutrition / Starvation
  • C — Constipation / Urinary retention
  • H — Hydration (dehydration) / Hypoxia

M — Medication (anticholinergics, benzodiazepines, opioids, polypharmacy) / Metabolic (electrolyte derangements)

E — Environment (room changes, sensory deprivation, sleep cycle disruption)

Delirium Management: First-line therapy is non-pharmacological and environmental : frequent verbal reorientation, presence of family members, ensuring sensory aids (glasses and hearing aids) are in place, single quiet room with natural daylight, visible clock/calendar, early mobilization, and avoiding physical restraints. Pharmacotherapy (low-dose oral haloperidol 0.25 − 0.5 mg 0.25 - 0.5\text{ mg} 0.25 − 0.5 mg or risperidone 0.25 − 0.5 mg 0.25 - 0.5\text{ mg} 0.25 − 0.5 mg ) is reserved strictly for severe distress or intractable agitation where the patient poses immediate danger to themselves or others, using the lowest effective dose for < 48 − 72 hours < 48-72\text{ hours} < 48 − 72 hours .

2. Falls Risk Assessment & Deprescribing

Falls Assessment: Multidisciplinary assessment includes history of falls, mobility testing using the Timed Up and Go (TUG) test (time > 12 seconds > 12\text{ seconds} > 12 seconds indicates heightened fall risk), environmental hazard inspection, vision screening, and targeted physical therapy.

Deprescribing & Beers Criteria: Reviewing and ceasing potentially inappropriate medications in older adults:

  • Anticholinergics and sedating antihistamines (urinary retention, delirium, cognitive decline)
  • Benzodiazepines and Z-drugs (falls, hip fractures, motor vehicle accidents)
  • Tertiary tricyclic antidepressants (postural hypotension, cardiac conduction delay)

Non-steroidal anti-inflammatory drugs (gastric ulceration, worsening renal function, heart failure decompensation)

Antihypertensives in patients with severe orthostatic hypotension (fall risk)

Frailty Syndrome: Characterized by diminished physiological reserve across multiple organ systems. Assessed using the Fried Frailty Phenotype (unintentional weight loss > 4.5 kg > 4.5\text{ kg} > 4.5 kg in 1 year, exhaustion, weak grip strength, slow walking speed, low physical activity; ≥ 3 \ge 3 ≥ 3 criteria confirms frailty).

Primary references (checked 7 October 2026): RACGP thrombocytopenia assessment .